

31.10.2020

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 524669

Symbol: HESTERBIO

Respected Sir / Madam:

Subject: Outcome of Board Meeting

This is with reference to our letter dated 23.10.2020 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended on 30.09.2020.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended on 30.09.2020.

We attach herewith:

- 1) The approved Standalone and Consolidated Unaudited Financial Results and Limited Review Reports.
- 2) Press Release issued in this regard

We would be publishing the extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 10:30 a.m. and concluded at 11:00 a.m.

You are requested to take the above information on your record.

Sincerely,
For Hester Biosciences Limited



Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED ON 30 SEPTEMBER 2020

Sr.	Particulars	In Million INR					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Net Sales/ Income from Operations	536.23	388.77	413.69	925.01	837.96	1,694.25
2	Other Income	4.75	4.18	6.54	8.94	19.72	29.27
3	Total Revenue (1+2)	540.98	392.96	420.23	933.94	857.68	1,723.52
4	Total Expenses	401.11	288.86	325.61	689.96	616.52	1,311.24
	(a) Cost of material consumed	38.96	31.86	48.91	70.83	102.68	211.31
	(b) Purchases of stock-in-trade	54.04	33.52	50.74	87.56	81.36	171.89
	(c) Change in inventories	52.60	(5.72)	(43.23)	46.88	(68.68)	(155.74)
	(d) Employee benefits expenses	75.79	74.47	92.07	150.26	170.44	371.57
	(e) Finance cost	15.73	9.64	6.06	25.37	18.48	50.34
	(f) Depreciation and amortisation expenses	23.91	23.61	23.25	47.51	46.52	93.85
	(g) Other expenses	140.08	121.47	147.81	261.55	265.72	568.03
5	Profit before tax (3-4)	139.88	104.10	94.62	243.98	241.16	412.29
6	Tax Expense	38.61	27.86	7.68	66.47	56.24	100.05
	Current tax	38.25	29.06	20.08	67.30	68.49	118.05
	Deffered tax	0.36	(1.19)	(12.40)	(0.83)	(12.25)	(18.00)
7	Profit for the period (5-6)	101.27	76.24	86.94	177.51	184.92	312.24
8	Other Comprehensive Income	2.42	(1.00)	(2.30)	1.42	(2.90)	(4.01)
	A (i) Items that will not be reclassified to Profit or Loss	3.24	(1.34)	(3.04)	1.90	(3.88)	(5.36)
	(ii) Income Tax realting to items that will not be reclassified to profit or loss	(0.82)	0.34	0.74	(0.48)	0.98	1.35
	B (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax realting to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7+8)	103.69	75.25	84.64	178.93	182.02	308.23
10	Paid-up equity share capital (face value of INR 10)	85.07	85.07	85.07	85.07	85.07	85.07
11	Reserve as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,945.73
12	Earnings Per Share (of INR 10 each) (Not Annualised) - Basic & Diluted	11.90	8.96	10.22	20.87	21.74	36.70

REPORT ON SEGMENT REVENUE, RESULTS, ASSETS AND LIABILITIES

Sr.	Particulars	In Million INR					
		Quarter Ended			Half Year Ended		Year Ended
		30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Segment Revenue						
	a. Poultry Healthcare	343.43	298.24	268.65	641.68	602.16	1,203.46
	b. Animal Healthcare	140.35	68.95	90.88	209.30	146.49	308.37
	c. Others	52.45	21.58	54.16	74.03	89.31	182.42
	Total Income from Operations (Net)	536.23	388.77	413.69	925.01	837.96	1,694.25
2	Segment Results (Profit before Finance Cost and Taxes)						
	a. Poultry Healthcare	55.76	63.84	47.65	119.60	174.02	300.70
	b. Animal Healthcare	47.39	28.33	13.84	75.72	29.77	38.39
	c. Others	52.46	21.57	39.19	74.03	55.85	123.54
	Total Segment Results	155.61	113.74	100.68	269.35	259.64	462.63
	a. Finance Costs	15.73	9.64	6.06	25.37	18.48	50.34
	b. Exceptional Items	-	-	-	-	-	-
	c. Other unallocable expenditure/(income) [Net]	-	-	-	-	-	-
	Profit before Tax	139.88	104.10	94.62	243.98	241.16	412.29
3	Segment Assets						
	a. Poultry Healthcare	-	-	-	2,081.73	1,926.85	2,148.31
	b. Animal Healthcare	-	-	-	211.95	337.21	144.77
	Unallocated Assets	-	-	-	468.25	394.54	457.57
	Total	-	-	-	2,761.93	2,658.60	2,750.65
4	Segment Liabilities						
	a. Poultry Healthcare	-	-	-	489.03	417.55	603.14
	b. Animal Healthcare	-	-	-	36.78	247.83	33.82
	Unallocated Liabilities	-	-	-	82.53	88.64	82.89
	Total	-	-	-	608.34	754.02	719.84

UNAUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES			
In Million INR			
Sr.	Particulars	As at	As at
		30-09-2020	30-09-2019
		Unaudited	Audited
I	Assets		
A	Non-current Assets		
	(a) Property, plant and equipment	929.22	984.76
	(b) Intangible Assets	8.74	4.39
	(c) Capital Work in progress	5.98	8.50
	(d) Biological Assets other than bearer plants	3.40	2.35
	(e) Financial Assets		
	(i) Investment	414.96	282.19
	(ii) Loans	53.30	48.66
	(iii) Other Financial Assets	53.05	36.86
	(f) Other non-current assets	46.59	49.46
	Total Non-Current Assets	1,515.24	1,417.17
B	Current Assets		
	(a) Inventories	573.19	554.83
	(b) Financial Assets		
	(i) Trade Receivables	516.23	391.79
	(ii) Cash & Cash Equivalents	11.99	148.01
	(iii) Other Bank Balances	-	4.03
	(iv) Others	-	5.83
	(c) Other Current Assets	5.68	131.81
	(d) Current Tax Assets	139.60	5.13
	Total Current Assets	1,246.69	1,241.44
	Total Assets	2,761.93	2,658.60
II	Equities & Liabilities		
C	Equity		
	(a) Equity Share capital	85.07	85.07
	(b) Other Equity	2,068.52	1,819.51
	Total Equity	2,153.59	1,904.58
	Liabilities		
D	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	62.42	102.26
	(ii) Other financial liabilities	3.03	1.20
	(b) Deferred tax liabilities (Net)	82.54	88.64
	(c) Other non-current liabilities		
	Total Non-Current Liabilities	147.98	192.11
E	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	139.78	361.33
	(ii) Trade Payables	110.29	83.92
	(iii) Other financial liabilities	138.03	84.70
	(b) Provisions	-	-
	(c) Other current liabilities	48.76	31.97
	(d) Current Tax Liabilities (Net)	23.50	-
	Total Current Liabilities	460.36	561.92
	Total Liabilities	608.34	719.84
	Total Equity & Liabilities	2,761.93	2,658.60

UNAUDITED STANDALONE CASHFLOW STATEMENT

In Million INR

Sr.	Particulars	As at	As at	As at
		30-09-2020	30-09-2019	31-03-2020
		Unaudited	Unaudited	Audited
A.	Cash Flow from Operating Activities			
	Net Profit Before Tax as Per Profit & Loss statement	243.98	241.15	412.29
	Adjustments For:			
	Depreciation and Amortisation Expense	47.51	46.52	93.85
	Bad Debts Written off	-	0.61	0.62
	(Profit) / Loss on Sale of Property, Plant & Equipments	-	-	(5.31)
	Finance Cost	25.37	18.48	50.34
	Interest & Commission Income	(8.33)	(14.33)	(15.38)
	Unrealised Foreign Exchange Gain	-	-	(6.39)
	Remeasurement of Net Defined Benefit Plans	1.90	(3.88)	(5.36)
	Operating Profit / (Loss) Before Changes in Working Capital	310.44	288.55	524.66
	Adjustments For:			
	Trade Receivables	(68.62)	(65.70)	(115.13)
	Inventories	31.13	(69.87)	(119.36)
	Other Current and Non Current Assets	(33.84)	(6.42)	19.75
	Trade Payables	(11.70)	3.43	41.50
	Other Current Liabilities	27.51	9.14	0.95
	Short-term Provisions	(0.01)	(2.59)	(2.58)
	Loans & Advances	(1.47)	2.77	5.43
	Other Financial Liability	39.82	6.99	20.51
	Other Financial Assets	-	(22.76)	(5.18)
	Cash Generated From Operations	293.27	143.57	370.56
	Net Income Tax (paid) / refunds	(45.06)	(57.75)	(106.24)
	Net Cash Flow from / (used in) Operating Activities (A)	248.21	85.81	264.32
B.	Cash Flow from Investing Activities			
	Proceeds from sale of Property, Plant & Equipments	-	-	9.81
	Investment in Subsidiary Companies	(8.25)	-	(124.52)
	Capital Expenditure on Property, Plant & Equipments	(15.73)	(34.25)	(62.47)
	Interest & Commission Income	8.33	14.33	15.38
	Investment in Bank Deposits	3.78	10.22	(23.30)
	Net Cash Flow from / (used in) Investing Activities (B)	(11.87)	(9.70)	(185.10)
C.	Cash Flow from Financing Activities			
	Proceeds/(Repayment) of Short-term Borrowings	(178.23)	151.96	108.64
	Interest Paid	(25.37)	(18.48)	(50.34)
	Dividend Paid (Including Dividend Distribution Tax)	(56.15)	(71.79)	(71.79)
	Proceeds/(Repayment) of Long Term Borrowing	(12.03)	(10.71)	(39.22)
	Net Cash Flow from / (used in) Financing Activities (C)	(271.78)	50.98	(52.71)
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(35.44)	127.09	26.52
	Cash and Cash Equivalents at the beginning of the year	47.44	20.92	20.92
	Cash and Cash Equivalents at the end of the year [Note No. 12]	11.99	148.01	47.44
	Major Components of Cash & Cash Equivalents			
	Cash on Hand	2.72	6.64	1.66
	Balance with Banks - On Current Accounts	9.27	141.37	10.78
	Fixed Deposits having maturity of less than 3 Months	-	-	35.00
	Total Cash & Cash Equivalents	11.99	148.01	47.44



Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +9179 26445106

Plant Address
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 79 26445105

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

- 1 The Unaudited Standalone Financial Results for the quarter and half year ended on 30 September 2020 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on 31 October 2020.
- 2 The Unaudited Standalone Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015.
- 3 Segment wise reporting in accordance with Ind AS 108 is given separately.
- 4 The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

For and on behalf of the Board of Directors

Place: Ahmedabad
Date: 31.10.2020

Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30 SEPTEMBER 2020

In Million INR							
Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Net Sales/ Income from Operations	534.10	398.53	441.98	932.63	889.56	1,832.68
2	Other Income	2.43	6.94	6.97	9.37	12.72	63.66
3	Total Revenue (1+2)	536.53	405.47	448.95	942.00	902.28	1,896.34
4	Total Expenses	429.60	326.63	377.82	756.23	700.94	1,483.09
	(a) Cost of material consumed	60.38	46.75	75.15	107.13	151.19	293.59
	(b) Purchases of stock-in-trade	19.16	9.98	20.93	29.14	27.55	65.16
	(c) Change in inventories	59.75	(7.12)	(40.32)	52.63	(67.23)	(161.68)
	(d) Employee benefits expenses	84.20	85.67	93.55	169.87	179.72	406.51
	(e) Finance cost	21.11	15.35	14.12	36.46	33.11	73.70
	(f) Depreciation and amortisation expenses	32.42	31.76	32.27	64.18	64.54	130.72
	(g) Other expenses	152.58	144.24	182.13	296.82	312.06	675.07
5	Profit before tax (3-4)	106.93	78.84	71.12	185.77	201.34	413.25
6	Tax Expense	40.11	28.34	9.05	68.45	58.41	103.24
	Current tax	39.72	29.53	21.45	69.25	70.66	121.67
	Deferred tax	0.39	(1.19)	(12.40)	(0.81)	(12.25)	(18.43)
7	Profit for the period (5-6)	66.82	50.50	62.08	117.32	142.93	310.02
8	Other Comprehensive Income	19.50	(0.25)	(6.29)	19.25	(5.90)	20.48
	A (i) Items that will not be reclassified to Profit or Loss	3.24	(1.34)	(3.04)	1.90	(3.88)	(5.36)
	(ii) Income Tax realting to items that will not be reclassified to profit or loss	(0.82)	0.34	0.74	(0.48)	0.98	1.35
	B (i) Items that will be reclassified to Profit or Loss	17.08	0.75	(3.99)	17.83	(3.00)	24.49
	(ii) Income Tax realting to items that will be reclassified to profit or loss	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7+8)	86.32	50.25	55.79	136.57	137.03	330.50
10	Profit for the period attributable to:						
	(i) Owners of the Company	66.82	57.15	65.24	123.97	149.11	291.71
	(ii) Non Controlling Interest	0.00	(6.65)	(3.16)	(6.64)	(6.18)	18.32
11	Other Comprehensive Income for the peiod attributable to:						
	(i) Owners of the Company	6.48	(0.25)	(6.30)	6.24	(5.90)	20.48
	(ii) Non Controlling Interest	13.02	-	-	13.02	-	(0.00)
12	Total Comprehensive Income for the peiod attributable to:						
	(i) Owners of the Company	73.30	56.90	58.94	130.20	143.21	312.19
	(ii) Non Controlling Interest	13.02	(6.65)	(3.16)	6.37	(6.18)	18.32
13	Paid-up equity share capital (face value of INR 10)	85.07	85.07	85.07	85.07	85.07	85.07
14	Reserve as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	1,925.65
15	Earnings Per Share (of INR 10 each) (Not Annualised) - Basic & Diluted	7.86	5.94	7.30	13.79	16.80	36.44

REPORT ON SEGMENT REVENUE, RESULTS, ASSETS AND LIABILITIES

In Million INR

Sr.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a. Poultry Healthcare	343.44	298.24	268.65	641.68	602.16	1,203.46
	b. Animal Healthcare	138.21	78.71	119.16	216.92	198.09	493.42
	c. Others	52.45	21.58	54.17	74.03	89.31	135.80
	Total Income from Operations (Net)	534.10	398.53	441.98	932.63	889.56	1,832.68
2	Segment Results (Profit before Finance Cost and Taxes)						
	a. Poultry Healthcare	55.76	63.84	47.65	119.60	185.14	300.70
	b. Animal Healthcare	19.83	8.77	23.59	28.60	29.77	101.28
	c. Others	52.45	21.58	2.89	74.03	19.54	84.98
	Total Segment Results	128.04	94.19	74.13	222.23	234.45	486.96
	a. Finance Costs	21.11	15.35	3.00	36.46	33.11	73.70
	b. Exceptional Items	-	-	-	-	-	-
	c. Other unallocable expenditure/(income) [Net]	-	-	-	-	-	-
	Profit before Tax	106.93	78.84	71.13	185.77	201.34	413.25
3	Segment Assets						
	a. Poultry Healthcare	-	-	-	2,081.73	1,926.85	2,148.31
	b. Animal Healthcare	-	-	-	211.95	337.21	144.77
	Unallocated Assets	-	-	-	2,043.74	1,222.28	1,551.69
	Total	-	-	-	4,337.42	3,486.34	3,844.77
4	Segment Liabilities						
	a. Poultry Healthcare	-	-	-	557.84	353.86	603.14
	b. Animal Healthcare	-	-	-	36.78	247.83	33.82
	Unallocated Liabilities	-	-	-	1,658.02	1,038.60	1,197.09
	Total	-	-	-	2,252.64	1,640.29	1,834.05

UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

In Million INR

Sr.	Particulars	As at	As at	As at
		30-09-2020	30-09-2019	31-03-2020
		Unaudited	Unaudited	Audited
I	Assets			
A	Non-current Assets			
	(a) Property, plant and equipment	2,442.53	1,409.93	1,368.56
	(b) Right to use Assets	49.20	-	49.99
	(c) Capital Work in progress	8.74	386.67	741.51
	(d) Intangible Assets	5.98	4.39	3.93
	(e) Biological Assets other than the Bearer Plants	3.40	2.35	2.90
	(f) Financial Assets			
	(i) Other Financial Assets	53.05	36.86	52.37
	(g) Other Non-current Assets	19.96	49.46	49.34
	Total Non-Current Assets	2,582.86	1,889.66	2,268.59
B	Current Assets			
	(a) Inventories	616.52	579.32	639.67
	(b) Financial Assets			
	(i) Trade Receivables	544.62	427.98	584.36
	(ii) Cash & Cash Equivalents	348.15	414.75	230.85
	(iii) Other Bank Balances	-	4.03	4.46
	(iv) Others	-	5.83	0.97
	(c) Current Tax Assets	5.69	3.97	4.34
	(d) Other Current Assets	239.58	160.79	111.53
	Total Current Assets	1,754.56	1,596.67	1,576.18
	Total Assets	4,337.42	3,486.34	3,844.77
II	Equities & Liabilities			
C	Equity			
	(a) Equity Share capital	85.07	85.07	85.07
	(b) Other Equity	1,999.71	1,760.98	1,925.65
	Equity attributable to Owners	2,084.78	1,846.05	2,010.72
	Non Controlling Interest	60.58	30.79	54.21
	Total Equity	2,145.36	1,876.84	2,064.93
	Liabilities			
D	Non-current liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	1,019.36	562.15	764.76
	(ii) Other financial liabilities	3.03	1.20	1.65
	(iii) Lease Liabilities	54.28	-	51.93
	(b) Deferred tax liabilities (Net)	87.85	94.35	88.17
	(c) Deferred Capital Grant	236.22	85.46	59.93
	Total Non-Current Liabilities	1,400.73	743.16	966.44
E	Current Liabilities			
	(a) Financial Liabilities			
	(i) Borrowings	186.51	385.51	325.42
	(ii) Trade Payables	124.00	210.29	186.14
	(iii) Other financial liabilities	173.77	115.39	132.82
	(iv) Lease Liabilities	-	-	3.22
	(b) Provisions	0.26	-	0.16
	(c) Other current liabilities	281.45	155.15	165.64
	(d) Current Tax Liabilities (Net)	25.34	-	-
	Total Current Liabilities	791.33	866.34	813.39
	Total Liabilities	2,192.06	1,609.50	1,779.84
	Total Equity & Liabilities	4,337.42	3,486.34	3,844.77

UNAUDITED CONSOLIDATED CASH FLOW STATEMENT

In Million INR

Sr.	Particulars	As at	As at	As at
		30-09-2020	30-09-2019	31-03-2020
		Unaudited	Unaudited	Audited
A.	Cash Flow from Operating Activities			
	Net Profit Before Tax as Per Profit & Loss statement	185.77	201.34	413.26
	Adjustments For:			
	Depreciation and Amortisation Expense	64.18	64.54	132.30
	Bad Debts Written off	-	0.61	0.62
	(Profit) / Loss on Sale of Property, Plant & Equipments	-	-	(5.31)
	Finance Cost	36.46	21.99	76.66
	Interest & Commission Income	(9.37)	(14.33)	(3.73)
	Unrealised Foreign Exchange Gain	-	-	(6.39)
	Loss on disposal of investment in subsidiary	-	-	0.74
	Preoperative Expenditure Written Off	-	-	7.56
	Remeasurement of Net Defined Benefit Plans	1.90	(3.88)	(5.36)
	Operating Profit / (Loss) Before Changes in Working Capital	278.94	270.27	610.35
	Adjustments For:			
	Trade Receivables	39.74	(111.66)	(249.93)
	Inventories	23.15	(71.47)	(131.82)
	Other Current and Non Current Assets	(98.67)	(11.94)	25.73
	Trade Payables	(62.14)	122.78	98.63
	Other Current Liabilities	115.82	92.00	96.07
	Short-term Provisions	0.10	(2.59)	(2.43)
	Loans & Advances	0.97	(3.26)	1.61
	Other Financial Liability	42.33	86.73	30.84
	Other Financial Assets	(0.68)	(22.76)	(5.18)
	Cash Generated From Operations	339.55	348.11	473.86
	Net Income Tax (paid) / refunds	(45.26)	(58.35)	(109.36)
	Net Cash Flow from / (used in) Operating Activities	294.30	289.76	364.50
	Exchange rate fluctuation arising on consolidation	17.83	(2.96)	18.42
	Net Cash Flow from / (used in) Operating Activities (A)	312.13	286.81	382.92
B.	Cash Flow from Investing Activities			
	Proceeds from sale of Property, Plant & Equipments	-	-	9.81
	Capital Expenditure on Property, Plant & Equipments	(407.15)	(349.17)	(734.98)
	Interest & Commission Income	9.37	14.33	3.73
	Investment in Bank Deposits	4.46	10.22	(23.30)
	Net Cash Flow from / (used in) Investing Activities (B)	(393.32)	(324.62)	(744.73)
C.	Cash Flow from Financing Activities			
	Proceeds/(Repayment) of Short-term Borrowings	(138.92)	160.53	100.44
	Interest Paid	(36.46)	(21.99)	(76.66)
	Dividend Paid (Including Dividend Distribution Tax)	(56.15)	(71.79)	(71.79)
	Proceeds/(Repayment) of Long Term Borrowing	254.60	(20.66)	181.25
	Repayment of Lease Liabilities	(0.87)	-	(1.24)
	Receipt of Capital Grant	176.28	-	54.19
	Net Cash Flow from / (used in) Financing Activities (C)	198.49	46.09	186.19
	Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	117.30	8.28	(175.62)
	Cash and Cash Equivalents at the beginning of the year	230.85	406.47	406.47
	Cash and Cash Equivalents at the end of the year [Note No. 12]	348.15	414.75	230.85
	Major Components of Cash & Cash Equivalents			
	Cash on Hand	2.72	6.99	1.75
	Balance with Banks - On Current Accounts	345.43	406.69	194.10
	Fixed Deposits having maturity of less than 3 Months	-	1.07	35.00
	Total Cash & Cash Equivalents	348.15	414.75	230.85



Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +9179 26445106

Plant Address
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +9179 26445105

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

- 1 The Unaudited Consolidated Financial Results for the quarter and half year ended on 30 September 2020 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on 31 October 2020.
- 2 The Unaudited Consolidated Financial Results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015.
- 3 Segment wise reporting in accordance with Ind AS 108 is given separately.
- 4 Consolidated Financial Figures include results of following Subsidiary Companies:
 - a) Texas Lifesciences Private Limited
 - b) Hester Biosciences Nepal Private Limited
 - c) Hester Biosciences Africa Limited
 - d) Hester Biosciences Kenya Limited
 - e) Hester Biosciences Tanzania Limited (Step-down Subsidiary)
- 5 The figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.

For and on behalf of the Board of Directors

Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 31.10.2020